January 7, 2021
Astellas Pharma said on January 6 that the US FDA has accepted for priority review its overactive bladder (OAB) drug Myrbetriq (mirabegron) for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged three years and older. The FDA...read more